# Ultragenyx Pharmaceutical Inc clinical trials: 63 (2026)

ClinicalTrials.gov lists 63 trials with Ultragenyx Pharmaceutical Inc as lead sponsor, 5 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Ultragenyx Pharmaceutical Inc: 63 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/ultragenyx-pharmaceutical-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 63
- Recruiting or not yet: 5
- Read on: November 19, 2026

## Trials

The 25 newest of 63, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 2, 2026 | NCT07855562 | MPS IIIA Disease Monitoring Program | Ultragenyx Pharmaceutical Inc | Observational | Not yet recruiting | MPS IIIA, Sanfilippo Syndrome, Sanfilippo A, Mucopolysaccharidosis III | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855562) |
| April 6, 2026 | NCT07511556 | First-in-human Study of UX016 in GNEM | Ultragenyx Pharmaceutical Inc | Phase 1/2 | Recruiting | GNE Myopathy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07511556) |
| September 5, 2025 | NCT07157254 | A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS) | Ultragenyx Pharmaceutical Inc | Phase 2 | Terminated | Angelman Syndrome | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07157254) |
| October 10, 2024 | NCT06636383 | Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program | Ultragenyx Pharmaceutical Inc | Observational | Recruiting | Glycogen Storage Disease Type Ia | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06636383) |
| October 10, 2024 | NCT06636071 | Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta | Ultragenyx Pharmaceutical Inc | Phase 3 | Active not recruiting | Osteogenesis Imperfecta | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06636071) |
| September 27, 2024 | NCT06617429 | Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS) | Ultragenyx Pharmaceutical Inc | Phase 3 | Terminated | Angelman Syndrome | 129 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06617429) |
| May 16, 2024 | NCT06415344 | Long-term Extension of GTX-102 in Angelman Syndrome | Ultragenyx Pharmaceutical Inc | Phase 3 | Terminated | Angelman Syndrome | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06415344) |
| July 6, 2023 | NCT05933200 | A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD | Ultragenyx Pharmaceutical Inc | Phase 3 | Active not recruiting | Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05933200) |
| March 14, 2023 | NCT05768854 | Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta | Ultragenyx Pharmaceutical Inc | Phase 3 | Active not recruiting | Osteogenesis Imperfecta | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05768854) |
| April 25, 2022 | NCT05345171 | Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency | Ultragenyx Pharmaceutical Inc | Phase 3 | Active not recruiting | OTC Deficiency | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05345171) |
| April 5, 2022 | NCT05312697 | Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta | Ultragenyx Pharmaceutical Inc | Phase 2 | Terminated | Osteogenesis Imperfecta | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05312697) |
| January 19, 2022 | NCT05196165 | Clinical Survey Study to Assess Physical Function and the Incidence of Hypoglycemia in Participants With Glycogen Storage Disease Type III | Ultragenyx Pharmaceutical Inc | Observational | Terminated | Glycogen Storage Disease Type III | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05196165) |
| December 1, 2021 | NCT05139316 | A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type... | Ultragenyx Pharmaceutical Inc | Phase 3 | Completed | Glycogen Storage Disease Type IA | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05139316) |
| November 18, 2021 | NCT05125809 | Setrusumab vs Placebo for Osteogenesis Imperfecta | Ultragenyx Pharmaceutical Inc | Phase 2/3 | Active not recruiting | Osteogenesis Imperfecta | 183 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05125809) |
| August 4, 2021 | NCT04990388 | Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III) | Ultragenyx Pharmaceutical Inc | Phase 1/2 | Terminated | Glycogen Storage Disease Type III | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04990388) |
| June 1, 2021 | NCT04909346 | Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease | Ultragenyx Pharmaceutical Inc | Observational | Terminated | Ornithine Transcarbamylase Deficiency, Wilson Disease, Glycogen Storage Disease Type IA | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04909346) |
| May 13, 2021 | NCT04884815 | A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease | Ultragenyx Pharmaceutical Inc | Phase 1/2 | Active not recruiting | Wilson Disease | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04884815) |
| March 23, 2021 | NCT04812106 | Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program | Ultragenyx Pharmaceutical Inc | Observational | Terminated | Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04812106) |
| March 5, 2021 | NCT04783428 | Tumor-induced Osteomalacia Disease Monitoring Program | Ultragenyx Pharmaceutical Inc | Observational | Active not recruiting | Tumor-induced Osteomalacia (TIO) | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04783428) |
| January 22, 2021 | NCT04717453 | Study to Characterize Rate of Ureagenesis in Patients With Ornithine Transcarbamylase (OTC) Deficiency | Ultragenyx Pharmaceutical Inc | Observational | Terminated | Ornithine Transcarbamylase Deficiency | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04717453) |
| January 13, 2021 | NCT04708015 | Retrospective Study of Glucose Monitoring for Glycemic Control in Patients With GSDIa | Ultragenyx Pharmaceutical Inc | Observational | Completed | Glycogen Storage Disease Type IA | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04708015) |
| November 17, 2020 | NCT04632953 | Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program | Ultragenyx Pharmaceutical Inc | Observational | Active not recruiting | Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04632953) |
| October 5, 2020 | NCT04574830 | Study to Evaluate Biomarkers and Clinical Manifestations in Individuals With Glycogen Storage Disease Type III (GSD III) | Ultragenyx Pharmaceutical Inc | Observational | Completed | Glycogen Storage Disease Type III | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04574830) |
| August 28, 2020 | NCT04531189 | Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease | Ultragenyx Pharmaceutical Inc | Observational | Completed | Wilson Disease | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04531189) |
| April 24, 2020 | NCT04360265 | Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA | Ultragenyx Pharmaceutical Inc | Phase 3 | Enrolling by invitation | Mucopolysaccharidosis IIIA, MPS IIIA, Sanfilippo Syndrome, Sanfilippo A | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04360265) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 1 |
| Phase 1/2 | 9 |
| Phase 2 | 16 |
| Phase 2/3 | 2 |
| Phase 3 | 13 |
| Not applicable | 2 |
| Observational | 20 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 27 |
| Terminated | 16 |
| Active not recruiting | 10 |
| Recruiting | 4 |
| Withdrawn | 2 |
| Available | 2 |
| Enrolling by invitation | 1 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Distal myopathy, Nonaka type | 8 |
| Osteogenesis Imperfecta | 7 |
| Mucopolysaccharidosis VII | 6 |
| VLCAD deficiency | 6 |
| Ornithine Carbamoyltransferase Deficiency Disease | 6 |
| Hepatorenal form of glycogen storage disease | 5 |
| Glucose Metabolism Disorders | 5 |
| Rare Diseases | 5 |
| Glycogen Storage Disease Type I | 4 |
| Angelman Syndrome | 4 |
| Lysosomal Storage Diseases | 4 |
| Metabolic Diseases | 4 |
| Mucopolysaccharidosis III | 4 |
| Hepatolenticular Degeneration | 3 |
| Glut1 Deficiency Syndrome | 3 |
| Mucopolysaccharidoses | 3 |
| Glycogen Storage Disease Type III | 3 |
| Trifunctional Protein Deficiency With Myopathy And Neuropathy | 3 |
| Carnitine-Acylcarnitine Translocase Deficiency | 3 |
| Hemophilia B | 2 |
| Urea Cycle Disorders, Inborn | 2 |
| Oncogenic osteomalacia | 1 |
| Carbohydrate Metabolism, Inborn Errors | 1 |
| Genetic Diseases, Inborn | 1 |
| Bone Diseases, Metabolic | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Ultrasound imaging clinics in the United States](https://specstream.ai/data/businesses/ultrasound-imaging-clinics/united-states)
- [Animation studios in the United States](https://specstream.ai/data/businesses/animation-studios/united-states)
- [Bathroom remodelers in the United States](https://specstream.ai/data/businesses/bathroom-remodelers/united-states)
- [Cleaning products suppliers in the United States](https://specstream.ai/data/businesses/cleaning-products-suppliers/united-states)
- [Ear, nose and throat clinics in the United States](https://specstream.ai/data/businesses/ear-nose-and-throat-clinics/united-states)
